Compare Stocks: DARE, HRTX, ELOX, and ATHE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATHE Alterity Therapeutics	$3.12 +1.6%	$4.15	$2.66 ▼ $5.89	$56.46M	0.27	20,207 shs	22,656 shs
DARE Dare Bioscience	$0.77 +0.2%	$0.88	$0.69 ▼ $3.78	$15.21M	1.01	239,837 shs	69,570 shs
ELOX Eloxx Pharmaceuticals	$13.74 -9.5%	$16.80	$8.20 ▼ $23.40	$55.46M	-1960.42	23,214 shs	31,308 shs
HRTX Heron Therapeutics	$0.41 +13.4%	$0.34	$0.26 ▼ $1.58	$77.10M	1.62	2.59 million shs	3.48 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATHE Alterity Therapeutics	+1.63%	-9.57%	-30.67%	-42.54%	-27.61%
DARE Dare Bioscience	+0.16%	-8.23%	+7.42%	-61.71%	-66.23%
ELOX Eloxx Pharmaceuticals	-9.49%	-11.41%	-17.08%	+16.34%	+1,248,990.91%
HRTX Heron Therapeutics	+13.37%	+16.83%	+21.95%	-2.00%	-69.92%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATHE Alterity Therapeutics	$3.12 +1.6%	$4.15	$2.66 ▼ $5.89	$56.46M	0.27	20,207 shs	22,656 shs
DARE Dare Bioscience	$0.77 +0.2%	$0.88	$0.69 ▼ $3.78	$15.21M	1.01	239,837 shs	69,570 shs
ELOX Eloxx Pharmaceuticals	$13.74 -9.5%	$16.80	$8.20 ▼ $23.40	$55.46M	-1960.42	23,214 shs	31,308 shs
HRTX Heron Therapeutics	$0.41 +13.4%	$0.34	$0.26 ▼ $1.58	$77.10M	1.62	2.59 million shs	3.48 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATHE Alterity Therapeutics	+1.63%	-9.57%	-30.67%	-42.54%	-27.61%
DARE Dare Bioscience	+0.16%	-8.23%	+7.42%	-61.71%	-66.23%
ELOX Eloxx Pharmaceuticals	-9.49%	-11.41%	-17.08%	+16.34%	+1,248,990.91%
HRTX Heron Therapeutics	+13.37%	+16.83%	+21.95%	-2.00%	-69.92%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATHE Alterity Therapeutics	2.57	Moderate Buy	$10.00	220.51% Upside
DARE Dare Bioscience	2.33	Hold	$6.50	740.44% Upside
ELOX Eloxx Pharmaceuticals	3.00	Buy	$38.33	178.99% Upside
HRTX Heron Therapeutics	2.00	Hold	$2.00	392.49% Upside

Current Analyst Ratings Breakdown

Latest DARE, HRTX, ELOX, and ATHE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/18/2026	ELOX Eloxx Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Outperform	$32.00
9/18/2026	ELOX Eloxx Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy	$32.00
9/16/2026	DARE Dare Bioscience	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/15/2026	ATHE Alterity Therapeutics	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$10.00
9/15/2026	ATHE Alterity Therapeutics	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$10.00
9/14/2026	DARE Dare Bioscience	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$1.00
8/25/2026	DARE Dare Bioscience	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/24/2026	ELOX Eloxx Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$43.00
8/20/2026	ELOX Eloxx Pharmaceuticals	Lucid Cap Mkts Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/17/2026	DARE Dare Bioscience	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/17/2026	DARE Dare Bioscience	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 10/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATHE Alterity Therapeutics	N/A	N/A	N/A	N/A	$1.60 per share	N/A
DARE Dare Bioscience	$1.03M	14.77	N/A	N/A	$0.20 per share	3.87
ELOX Eloxx Pharmaceuticals	N/A	N/A	N/A	N/A	($85.17) per share	N/A
HRTX Heron Therapeutics	$154.90M	0.50	N/A	N/A	$0.07 per share	5.80

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATHE Alterity Therapeutics	-$15.88M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
DARE Dare Bioscience	-$13.40M	-$0.70	N/A	N/A	N/A	-803.80%	-748.30%	-38.75%	11/12/2026 (Estimated)
ELOX Eloxx Pharmaceuticals	-$5.99M	-$1.54	N/A	N/A	N/A	N/A	N/A	N/A	N/A
HRTX Heron Therapeutics	-$20.19M	-$0.19	N/A	N/A	N/A	-22.52%	-293.02%	-10.00%	11/3/2026 (Estimated)

Latest DARE, HRTX, ELOX, and ATHE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/3/2026	Q3 2026	HRTX Heron Therapeutics	-$0.03	N/A	N/A	N/A	$37.50 million	N/A
8/13/2026	Q2 2026	DARE Dare Bioscience	-$0.2967	-$0.20	+$0.0967	-$0.20	$0.00 million	$0.19 million
8/11/2026	Q2 2026	ELOX Eloxx Pharmaceuticals	N/A	-$0.66	N/A	-$0.66	N/A	N/A
8/10/2026	Q2 2026	HRTX Heron Therapeutics	-$0.0050	-$0.03	-$0.0250	-$0.03	$42.19 million	$37.67 million
7/30/2026	Q4 2026 TU	ATHE Alterity Therapeutics	N/A	-$0.28	N/A	-$0.28	N/A	$0.31 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATHE Alterity Therapeutics	N/A	N/A	N/A	N/A	N/A
DARE Dare Bioscience	N/A	N/A	N/A	N/A	N/A
ELOX Eloxx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
HRTX Heron Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATHE Alterity Therapeutics	N/A	14.52	14.52
DARE Dare Bioscience	N/A	0.99	0.99
ELOX Eloxx Pharmaceuticals	N/A	3.74	3.74
HRTX Heron Therapeutics	24.35	2.49	1.51

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATHE Alterity Therapeutics	2.14%
DARE Dare Bioscience	6.70%
ELOX Eloxx Pharmaceuticals	2.90%
HRTX Heron Therapeutics	80.01%

Insider Ownership

Company	Insider Ownership
ATHE Alterity Therapeutics	38.80%
DARE Dare Bioscience	4.10%
ELOX Eloxx Pharmaceuticals	25.90%
HRTX Heron Therapeutics	6.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATHE Alterity Therapeutics	11	18.13 million	11.09 million	Not Optionable
DARE Dare Bioscience	24	19.67 million	18.86 million	Not Optionable
ELOX Eloxx Pharmaceuticals	7	4.04 million	2.99 million	N/A
HRTX Heron Therapeutics	128	189.85 million	178.27 million	Optionable

DARE, HRTX, ELOX, and ATHE Headlines

Recent News About These Companies

Why Heron Therapeutics, Inc.’s (HRTX) Stock Is Up 10.43%

October 8 at 8:20 PM | aaii.comA

Heron Therapeutics stock gained 15.86 percent to USD 0.38

October 8 at 10:20 AM | ad-hoc-news.deA

Head-To-Head Survey: Perrigo (NYSE:PRGO) & Heron Therapeutics (NASDAQ:HRTX)

October 8 at 4:59 AM | americanbankingnews.com

Heron Therapeutics stock fell 2.33 percent on October 2

October 5, 2026 | ad-hoc-news.deA

Heron Therapeutics Secures Exclusive U.S. License in Multi-Product Agreement with Long Grove Pharmaceuticals

September 30, 2026 | kalkinemedia.comK

HRTX Pro Research (inglés)

September 30, 2026 | es.investing.com

Heron Therapeutics, Inc. (NASDAQ:HRTX) Receives Consensus Rating of "Hold" from Brokerages

September 30, 2026 | americanbankingnews.com

Heron Therapeutics firma un accordo di licenza multi-prodotto con Long Grove

September 29, 2026 | it.investing.com

Heron Therapeutics, Inc. (NASDAQ:HRTX) Stock Has Consensus Target Price of $2.00

September 25, 2026 | marketbeat.com

Heron Therapeutics stock awaits its next reported figures

September 22, 2026 | ad-hoc-news.deA

Heron Therapeutics Sees Unusually High Options Volume (NASDAQ:HRTX)

September 16, 2026 | marketbeat.com

Heron (HRTX) Q2 2026 Earnings Call Transcript

August 17, 2026 | finance.yahoo.com

Heron Therapeutics Extends Tax Benefit Preservation Plan Timeline

August 14, 2026 | tipranks.com

Heron Therapeutics: Q2 Earnings Snapshot

August 11, 2026 | aol.comA

Heron outlines covenants through 2027 and pro forma cash of $24.3M after September debt payment

August 11, 2026 | seekingalpha.com

Heron Therapeutics Announces Second Quarter 2026 Financial Results

August 11, 2026 | markets.businessinsider.com

Heron Therapeutics withdraws 2026 guidance as CINVANTI patent risk and strategic review cloud outlook

August 11, 2026 | msn.com

Heron Therapeutics (HRTX) Reports Q2 Loss, Lags Revenue Estimates

August 10, 2026 | zacks.com

Heron Therapeutics to Report Second Quarter 2026 Financial Results on August 10

July 27, 2026 | quiverquant.comQ

Heron Therapeutics to Report Second Quarter 2026 Financial Results on Monday, August 10, 2026

July 27, 2026 | globenewswire.com

New Strong Sell Stocks for July 15th

July 15, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DARE, HRTX, ELOX, and ATHE Company Descriptions

Alterity Therapeutics NASDAQ:ATHE

$3.12 +0.05 (+1.63%)

Closing price 10/9/2026 03:59 PM Eastern

Extended Trading

$3.12 0.00 (-0.16%)

As of 10/9/2026 07:30 PM Eastern

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Dare Bioscience NASDAQ:DARE

$0.77 +0.00 (+0.16%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$0.77 -0.01 (-0.83%)

As of 10/9/2026 07:08 PM Eastern

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.

Eloxx Pharmaceuticals NASDAQ:ELOX

$13.74 -1.44 (-9.49%)

As of 10/9/2026 04:00 PM Eastern

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company's lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States.

Heron Therapeutics NASDAQ:HRTX

$0.41 +0.05 (+13.37%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$0.40 0.00 (-0.52%)

As of 10/9/2026 07:45 PM Eastern

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DARE, HRTX, ELOX, and ATHE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DARE, HRTX, ELOX, and ATHE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DARE, HRTX, ELOX, and ATHE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DARE, HRTX, ELOX, and ATHE Company Descriptions

Alterity Therapeutics NASDAQ:ATHE

Dare Bioscience NASDAQ:DARE

Eloxx Pharmaceuticals NASDAQ:ELOX

Heron Therapeutics NASDAQ:HRTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DARE, HRTX, ELOX, and ATHE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DARE, HRTX, ELOX, and ATHE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DARE, HRTX, ELOX, and ATHE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DARE, HRTX, ELOX, and ATHE Company Descriptions

Alterity Therapeutics NASDAQ:ATHE

Dare Bioscience NASDAQ:DARE

Eloxx Pharmaceuticals NASDAQ:ELOX

Heron Therapeutics NASDAQ:HRTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools